We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| IntelliAM AI plc | AQSE:INT | Aquis Stock Exchange | Ordinary Share | GB00BR56LJ77 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 110.00 | 0.00 | 06:58:37 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 105.00 | 115.00 | 110.00 | 110.00 | 110.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | 110.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/7/2024 | 07:00 | UK RNS | IntelliAM AI PLC Contract |
| 08/7/2024 | 13:04 | UK RNS | IntelliAM AI PLC Holding(s) in Company |
| 04/7/2024 | 07:00 | UK RNS | IntelliAM AI PLC Acquisition |
| 03/7/2024 | 07:00 | UK RNS | IntelliAM AI PLC AQSE Only - Admission to Trading & First Dealings |
IntelliAM AI (INT) Share Charts1 Year IntelliAM AI Chart |
|
1 Month IntelliAM AI Chart |
Intraday IntelliAM AI Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/7/2024 | 15:24 | IntelliAM AI plc (AQSE: INT): AI for Manufacturing Sector | 2 |
| 15/6/2021 | 11:06 | Interest rates - next move - up or down? | 3 |
| 01/5/2011 | 14:04 | My bank manager thinks Base rates are going to 5% | 2 |
| 14/11/2008 | 12:22 | International Medical Devices - outstanding growth | 903 |
| 12/5/2008 | 15:21 | Ronaldo---buck toothed greedy bastard | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 03/7/2024 14:57 by hedgehog 100 "WEDNESDAY 03 JULY 2024 8:26 AMSouth Yorkshire firm Intelliam AI floats on the Aquis Stock Exchange By:Ali Lyon South Yorkshire AI firm Intelliam AI made its stock market debut this morning, floating on the Aquis Stock Exchange in a move that valued the firm at nearly £18m. The firm, which uses AI to improve operating efficiency in the manufacturing sector, raised over £5m with the listing, the proceeds from which it will use to acquire 53 Degrees North Group Limited, a consultancy firm. ... The listing is one of the first AIM and Machine firms to list on the Aquis Growth Market, a primary market for small and mid-cap firms. Intelliam already works with some of the world’s largest food and drinks firms, including the sweet and pet food giant Mars, for which it uses its machine learning technology to drive productivity improvements. Tom Clayton, Intelliam’s CEO, said: “We are delighted to be joining the AQSE Growth Market at a time when we have combined our established manufacturing asset management consultancy with our more recently developed and launched Intelliam AI platform. “We believe that this platform has immense and proven potential to reduce unscheduled manufacturing downtime, improve producer operating efficiencies and thereby increase our clients’ profitability.&rdquo The float comes despite Intelliam’s chair, David Richards, being asked by his former employer to repay hundreds of thousands of pounds by the board of his former company, Wandisco. Richards was boss of the tech firm, which he left shortly before the emergence of a major fraud which involved booking nearly £100m of false sales." |
Posted at 03/7/2024 14:45 by hedgehog 100 Current share price 3rd. July 2024: 105p16,382,534 shares in issue Market capitalisation: £17.2016M. "Transforming business with AI-powered Asset Management Unlock a new dimension of efficiency, innovation and success." "About IntelliAM AI Plc IntelliAM AI Plc is a software company leveraging the power of AI and machine learning in the manufacturing industry. IntelliAM uses AI models to proactively increase operating efficiency of the existing assets of the Company’s manufacturing clients. The Company achieves this by harnessing vast amounts of data from the client’s machines and operational systems processed through the IntelliAM platform to provide actionable insights for clients that encompass a broad range of areas, such as productivity, reliability and supply-chain optimisation, as well as energy efficiency and sustainability." 03 Jul 24 07:00 IntelliAM AI PLC - AQSE Only - Admission to Trading & First Dealings "Admission to Trading on AQSE and First Day of Dealings IntelliAM AI plc (AQSE: INT), the software company leveraging the power of AI and machine learning in the manufacturing industry, is pleased to announce that dealings in its Ordinary Shares of £0.005 each (Ordinary Shares) will commence from 8:00 am today, 3 July 2024, on the Aquis Stock Exchange Growth Market under the ticker symbol INT and ISIN number --GB00BR56LJ77. On Admission, and following a Placing that raised gross proceeds of £5,079,989, the Company will have 16,382,534 Ordinary Shares in issue and the market capitalisation of the Company will be approximately £15,399,582. Tomorrow, Thursday 4 July, the Company will complete the acquisition of 53 North and issue 2,759,042 Consideration Shares. Therefore, on 4 July the Company will have 19,141,576 shares in issue and, at the Placing Price of 94p, this would represent a market capitalisation of £17,993,081. A further announcement will be made tomorrow and details of the acquisition, and any terms not defined in this announcement, can be found in the Company's Admission Document at: About IntelliAM IntelliAM uses AI models to proactively increase operating efficiency of the existing assets of the Company's manufacturing clients. The Group achieves this by harnessing vast amounts of data from the client's machines and operational systems processed through the IntelliAM platform to provide actionable insights for clients that encompass a broad range of areas, such as productivity, reliability and supply-chain optimisation, as well as energy efficiency and sustainability. Tom Clayton, Chief Executive Officer of IntelliAM, said: "We are delighted to be joining the AQSE Growth Market at a time when we have combined our established manufacturing asset management consultancy with our more recently developed and launched IntelliAM AI platform. We believe that this platform has immense and proven potential to reduce unscheduled manufacturing downtime, improve producer operating efficiencies and thereby increase our clients' profitability." Enquiries: IntelliAM AI plc +44 114 299 5007 Tom Clayton, Chief Executive Officer Daud Khan, Chief Financial Officer Oberon Capital - AQSE Corporate Adviser and Broker +44 203 179 5300 Adam Pollock Mike Seabrook Jessica Cave Square1 Consulting - Financial PR +44 207 929 5599 David Bick +44 7831 381201" "IntelliAM AI starts trading on AQSE with £15 million market cap 03 July 2024, 12:03 Source - Alliance News The software company, leveraging the power of AI and machine learning in the manufacturing industry, said following a placing that raised £5.1 million gross, it will have 16.4 million shares in issue with a market capitalisation of around £15.4 million. The placing price was 94 pence per share. Shares in IntelliAM rose 11% to 104.0p each on Wednesday in London, implying a market value of around £17.1 million. It added that on Thursday, it will complete the acquisition of 53 North and issue 2.8 million consideration shares, meaning there will be 19.1 million shares in issue. Including the shares to be issued as part of the 53 North deal, the current 104p share price suggests a market value of around £19.9 million. Copyright 2024 Alliance News Ltd. All Rights Reserved." |
Posted at 17/7/2008 20:54 by 5huu One of my colleauges from legal (and a fellow IMD holder) contacted Shore today to discuss their take on the recent broker note. First call was with Robin Speakman, who strangely had no idea that IMD had put two of its subsidiaries into admistration. He admitted being aware of the share suspension though. When he was challenged on the content on his report, he was apparently quick to point out that it was simply a marketing resarch for a client based on IMD interims and that no contact had been made to discuss antything. Speakman aluded to Shore only being involved since Feb, He had no knowledge of Shore being the MM shifting shares after note issue & that he had no personal contact with IMD in preparing his research note. Apparently the only real relationship with IMD was between IMD & Guy Peters who is the member of the corporate team (Speakman is not). Peters was unavailable for comment. Speakman also mentioned that the negative current asset situ in the interims was not unusual for a small growing company.Initial legal stance is that someone is liable - Either Shore for a poorly researched note and/or failing to represent financial data correctly, or IMD who have lied during the interims and lied to their brokers. My colleauge is weighing up the legal case against Shore based on Shore not fulfiling their responsibilities under FSA guidlelines. The LSE have now been informed of all the facts and a summary of the situation with these dodgy IMD Directors that have history (TVR & ISIS). Apparently Mike Acheson was also unavailable for comment today too. I'll post progress, I'd appreciate if others would to. This gets smellier, the deeper we dig. |
Posted at 23/6/2008 14:13 by pomp circumstance from what i understood a rights issue wasnt on the cards.But nothing that wasnt public domain was said. From another source I understood the takeover was a RTO and was to be funded by a mixture of equity and debt at a considerably higher price than the current share price However it fell thru due to problems out of the hands of the company even tho both parties were keen to progress the transaction! But this is AIM and the share price is dropping at a disturning rate so who knows what is truth and what is hype. On published figures they look to be undervalued and oversold! |
Posted at 22/6/2008 22:58 by knowing ReminderIMD has reported a solid set of interim results, above our expectations at the revenue, operating profit, adjusted PBT and EPS levels. The period saw further restructuring costs and an aborted acquisition which revealed an exceptional cost of c£1.3m the outlook remains robust in the defensive healthcare sector (we expect growth of between 7% and 11% in the medical equipment and consumables markets). We expect the current half through to August 2008 to show a clean period of profitable trading and this pulls through an upgrade to our expectations (for the current year and thereafter). The long-term outlook remains positive for organic growth, building upon the acquisitions made to date. IMD's strategy remains to build operations by buying businesses and to grow these by consolidation of these into the group sales and distribution infrastructure. The company reported H1 2007 revenues of c£5.1m; we had pencilled in IMD generating sales of c£5.8m for H1 2008. The out-turn of c£6.2m is thus pleasing the company had the full benefit of recent acquisitions, though restructuring was still being completed with businesses being relocated and management systems implemented. Holding our revenue forecast for the full year to August at current levels indicates a comfortable revenue target (in light of management's robust comments on the outlook) for the current half of £6.3m. At the adjusted PBT level, we were expecting a H1 figure of around £160k with operations still building from consolidation of the acquisitions into the group. Tight operational cost control and synergies beginning to emerge revealed adjusted PBT for the period of c£300k this is an encouraging number to us given the prospects for positive operational gearing from emerging economies of scale. Our EPS expectation was 0.04p compared to the result of 0.09p. An exceptional charge pushed IMD into a loss position for the period at the reported level. This consisted of a mix of restructuring costs relating to management efficiencies, relocation costs and an aborted acquisition cost. IMD is now operating from just two sites: in Selby, Yorkshire and in Gloucester. We believe that the Selby operations in particular offer the prospect for additional scale economies. The opportunity to build the business with further acquisitions remains. IMD is now operating through three divisions in Acute Care (focused upon hospital equipment and consumables), Devices (needles and specialist treatment equipment) and in Aged Care (covering specialist products for the wider market). Aged Care has seen some frustrating operational issues that have held back sales and operating margins in particular concerned with the product range. These appear well on the way to being resolved with additional product supply agreements being targeted. Sales of safety needles (Surety) have now commenced with the first orders being received from the NHS. Management is now looking at the prospects for international sales of safety needles, in particular applying for FDA approval in the USA with a third party local distributor based in Canada. Holding our revenue forecast steady for the full year (holding out for the prospect of a further upgrade), our profit expectation increases with the restructuring benefits coming through; we therefore lower our cost base expectations. The benefits of the restructuring costs incurred in H1 appear be self-funding over the next 12 months. Our FY2008 adjusted PBT forecast rises from £0.5m to £0.6m and for FY2009 from £0.7m to £1.5m with an additional c£1.0m of revenue now expected for the next financial year. Our FY2008 EPS expectation rises from 0.20p to 0.23p, but for FY2009F this rises from 0.22p to 0.33p. IMD has seen considerable management change in the period with a new executive team taking over group operations under the experienced Bill McGrath. We believe that this change heralds the emergence of revenue and profit momentum for the company. IMD's operations are growing and profitable and we now expect the company to begin to generate free cash flows. The valuation is inexpensive on a FY2009F PER of c3.6x (EV/EBITDA 3.0x) and a free cash flow yield of over 27%. We also note that the company trades well below its prospective NAV per share of c6.1p. |
Posted at 29/5/2008 05:51 by pomp circumstance Its a crying shame they werent able to procede with the corporate action.I intimated I thought this was their plan with the move to Shore and the comment from a director somewhile ago that they were so interested in million pund bolt-ons. From what i understand, the corporate action is not dead in the water. There is still a chance it might go thru at some point but their are a couple of issues that the other party need to resolve. From what i understand it would be immediately earnings enhancing and a good deal for both parties. As for cash, while cash balance are low, the business is cash generative and they have very good support from their bankers and shore capital, who were very supportive of the proposed corporate action. In the CEO we have a man of years of experience of building and integrating business and the chairman is very well connected. I dont see too many risks with INT, organic growth is slower bit looking good, and if thy can pull of a deal or two to enhance the size of the company, it will start to get more notice. I think Shore need to step up and bring in an extra institution or two who will mop up the overhang. Ive asked the question and it doesnt seem to be one party selling, but when the sales go thru they are often at below bid, so we are having the opportunity to buy into this exciting little company at rock bottom. I personally picked up another 300k yday at 1.25p, i expect them to be worth at leats 4p by the end of the year and more if the corporate action can be concluded. |
Posted at 28/5/2008 22:13 by tornadodown Well worth another read and maybe James can get a link to incorporate into the headerInternational Medical Devices+ (INT.L) Interim results NR*, 1.2p Yr-end Sales Mkt Cap/ Adj PBT RptdPBT EPS PER FCF Yield EV/EBITDA Aug (£m) Sales (x) (£m) (£m) (p) (x) (%) (x) 2007A 11.2 0.3 0.5 0.5 0.17 6.9 -14.1% 7.1 2008F 12.5 0.3 0.6 (0.7) 0.23 5.3 12.7% 6.1 2009F 14.5 0.3 1.5 1.5 0.33 3.6 27.1% 3.0 2010F 15.8 0.2 2.0 1.5 0.43 2.8 38.1% 1.8 Source: IMD, Shore Capital Stockbrokers IMD has reported a solid set of interim results, above our expectations at the revenue, operating profit, adjusted PBT and EPS levels. The period saw further restructuring costs and an aborted acquisition which revealed an exceptional cost of c£1.3m the outlook remains robust in the defensive healthcare sector (we expect growth of between 7% and 11% in the medical equipment and onsumables markets). We expect the current half through to August 2008 to show a clean period of profitable trading and this pulls through an upgrade to our expectations (for the current year and thereafter). The long-term outlook remains positive for organic growth, building upon the acquisitions made to date. IMD's strategy remains to build operations by buying businesses and to grow these by consolidation of these into the group sales and distribution infrastructure. The company reported H1 2007 revenues of c£5.1m; we had pencilled in IMD generating sales of c£5.8m for H1 2008. The out-turn of c£6.2m is thus pleasing the company had the full benefit of recent acquisitions, though restructuring was still being completed with businesses being relocated and management systems implemented. Holding our revenue forecast for the full year to August at current levels indicates a comfortable revenue target (in light of management's robust comments on the outlook) for the current half of £6.3m. At the adjusted PBT level, we were expecting a H1 figure of around £160k with operations still building from consolidation of the acquisitions into the group. Tight operational cost control and synergies beginning to emerge revealed adjusted PBT for the period of c£300k this is an encouraging number to us given the prospects for positive operational gearing from emerging economies of scale. Our EPS expectation was 0.04p compared to the result of 0.09p. An exceptional charge pushed IMD into a loss position for the period at the reported level. This consisted of a mix of restructuring costs relating to management efficiencies, relocation costs and an aborted acquisition cost. IMD is now operating from just two sites: in Selby, Yorkshire and in Gloucester. We believe that the Selby operations in particular offer the prospect for additional scale economies. The opportunity to build the business with further acquisitions remains. IMD is now operating through three divisions in Acute Care (focused upon hospital equipment and consumables), Devices (needles and specialist treatment equipment) and in Aged Care (covering specialist products for the wider market). Aged Care has seen some frustrating operational issues that have held back sales and operating margins in particular concerned with the product range. These appear well on the way to being resolved with additional product supply agreements being targeted. Sales of safety needles (Surety) have now commenced with the first orders being received from the NHS. Management is now looking at the prospects for international sales of safety needles, in particular applying for FDA approval in the USA with a third party local distributor based in Canada. Holding our revenue forecast steady for the full year (holding out for the prospect of a further upgrade), our profit expectation increases with the restructuring benefits coming through; we therefore lower our cost base expectations. The benefits of the restructuring costs incurred in H1 appear be self-funding over the next 12 months. Our FY2008 adjusted PBT forecast rises from £0.5m to £0.6m and for FY2009 from £0.7m to £1.5m with an additional c£1.0m of revenue now expected for the next financial year. Our FY2008 EPS expectation rises from 0.20p to 0.23p, but for FY2009F this rises from 0.22p to 0.33p. IMD has seen considerable management change in the period with a new executive team taking over group operations under the experienced Bill McGrath. We believe that this change heralds the emergence of revenue and profit momentum for the company. IMD's operations are growing and profitable and we now expect the company to begin to generate free cash flows. The valuation is inexpensive on a FY2009F PER of c3.6x (EV/EBITDA 3.0x) and a free cash flow yield of over 27%. We also note that the company trades well below its prospective NAV per share of c6.1p. |
Posted at 28/5/2008 12:33 by cyberpost broker note from Shore :International Medical Devices+ (INT.L) Interim results NR*, 1.2p Yr-end Sales Mkt Cap/ Adj PBT RptdPBT EPS PER FCF Yield EV/EBITDA Aug (£m) Sales (x) (£m) (£m) (p) (x) (%) (x) 2007A 11.2 0.3 0.5 0.5 0.17 6.9 -14.1% 7.1 2008F 12.5 0.3 0.6 (0.7) 0.23 5.3 12.7% 6.1 2009F 14.5 0.3 1.5 1.5 0.33 3.6 27.1% 3.0 2010F 15.8 0.2 2.0 1.5 0.43 2.8 38.1% 1.8 Source: IMD, Shore Capital Stockbrokers IMD has reported a solid set of interim results, above our expectations at the revenue, operating profit, adjusted PBT and EPS levels. The period saw further restructuring costs and an aborted acquisition which revealed an exceptional cost of c£1.3m the outlook remains robust in the defensive healthcare sector (we expect growth of between 7% and 11% in the medical equipment and onsumables markets). We expect the current half through to August 2008 to show a clean period of profitable trading and this pulls through an upgrade to our expectations (for the current year and thereafter). The long-term outlook remains positive for organic growth, building upon the acquisitions made to date. IMD's strategy remains to build operations by buying businesses and to grow these by consolidation of these into the group sales and distribution infrastructure. The company reported H1 2007 revenues of c£5.1m; we had pencilled in IMD generating sales of c£5.8m for H1 2008. The out-turn of c£6.2m is thus pleasing the company had the full benefit of recent acquisitions, though restructuring was still being completed with businesses being relocated and management systems implemented. Holding our revenue forecast for the full year to August at current levels indicates a comfortable revenue target (in light of management's robust comments on the outlook) for the current half of £6.3m. At the adjusted PBT level, we were expecting a H1 figure of around £160k with operations still building from consolidation of the acquisitions into the group. Tight operational cost control and synergies beginning to emerge revealed adjusted PBT for the period of c£300k this is an encouraging number to us given the prospects for positive operational gearing from emerging economies of scale. Our EPS expectation was 0.04p compared to the result of 0.09p. An exceptional charge pushed IMD into a loss position for the period at the reported level. This consisted of a mix of restructuring costs relating to management efficiencies, relocation costs and an aborted acquisition cost. IMD is now operating from just two sites: in Selby, Yorkshire and in Gloucester. We believe that the Selby operations in particular offer the prospect for additional scale economies. The opportunity to build the business with further acquisitions remains. IMD is now operating through three divisions in Acute Care (focused upon hospital equipment and consumables), Devices (needles and specialist treatment equipment) and in Aged Care (covering specialist products for the wider market). Aged Care has seen some frustrating operational issues that have held back sales and operating margins in particular concerned with the product range. These appear well on the way to being resolved with additional product supply agreements being targeted. Sales of safety needles (Surety) have now commenced with the first orders being received from the NHS. Management is now looking at the prospects for international sales of safety needles, in particular applying for FDA approval in the USA with a third party local distributor based in Canada. Holding our revenue forecast steady for the full year (holding out for the prospect of a further upgrade), our profit expectation increases with the restructuring benefits coming through; we therefore lower our cost base expectations. The benefits of the restructuring costs incurred in H1 appear be self-funding over the next 12 months. Our FY2008 adjusted PBT forecast rises from £0.5m to £0.6m and for FY2009 from £0.7m to £1.5m with an additional c£1.0m of revenue now expected for the next financial year. Our FY2008 EPS expectation rises from 0.20p to 0.23p, but for FY2009F this rises from 0.22p to 0.33p. IMD has seen considerable management change in the period with a new executive team taking over group operations under the experienced Bill McGrath. We believe that this change heralds the emergence of revenue and profit momentum for the company. IMD's operations are growing and profitable and we now expect the company to begin to generate free cash flows. The valuation is inexpensive on a FY2009F PER of c3.6x (EV/EBITDA 3.0x) and a free cash flow yield of over 27%. We also note that the company trades well below its prospective NAV per share of c6.1p. |
Posted at 30/1/2008 11:28 by ged5 I thought there were just 2 things holding back the share price 1. The presence of Chris Thomas as CEO (another poster's view not fully mine) 2. The lack of contracts for the "Clip-on" syringe or Surety Needle as it's now called. Well we had the announcement on 3rd December that Chris Thomas was moving on and yet we only had a deterioration in the share price Now we've had this news about the Surety Needle being endorsed. The announcement is spurious to say the least as is the one from July. My reading of the situation is that IMD will now be on a list with any other safety needle. Am I correct in this thinking? Nowhere has exclusive agreement been mentioned. Also all the figures quoted in the 2 statements relate to the NHS not to IMD. I was fairly disappointed with the share price after yesterday's announcement but on reflection the pieces of the jigsaw are gradually being put into place. I think there's still plenty of work to be done but if the Surety Needle is as good as claimed then there's absolutely no reason why we shouldn't make headway towards the broker's 6p target price and beyond. |
Posted at 07/12/2007 07:25 by pomp circumstance good news!!! (or is it!!)7 December 2007 International Medical Devices plc ("IMD" or "the Company") Directors Remuneration and Convertible Loan Note International Medical Devices plc (AIM: INT), the medical supply company targeting the acute care, aged care, and devices markets, announces that its new CEO has agreed to take part of his remuneration in shares above the current market price, and that it has signed a convertible loan note. Bill McGrath joined the company as Chief Operating Officer on 2 November 2007, and became the Company's Chief Executive Officer on 3 December 2007. He has agreed to convert, in aggregate #70,000 of his remuneration into Ordinary Shares, at a price higher than today's market price, being 1,125,000 Ordinary Shares at 4p and 500,000 Ordinary Shares at 5p, being a total of 1,625,000 Ordinary Shares. The Company has also entered into a two year loan note with Trafalgar Capital Specialized Investment Fund amounting to #600,000 which carries conversion rights into Ordinary shares. IMD intends to utilise the funds in support of the Company's "buy and build" strategy, relating to potential acquisition opportunities. The provider has been issued 329,272 Ordinary Shares on entering into the agreement. Application has been made for the above 1,954,272 Ordinary Shares to be admitted to trading on AIM. It is expected that admission to trading on AIM will be effected and dealings in these new Ordinary Shares will commence on 13 December 2007. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
